Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMDGlobeNewsWire • 06/28/22
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe DiseaseGlobeNewsWire • 06/28/22
Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicronMarket Watch • 06/24/22
Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccineGlobeNewsWire • 06/24/22
Bridgewater's bearish bets on European stocks jump to $10.5 billion - Bloomberg NewsReuters • 06/23/22
Why These 5 European Dividend Aristocrats (Some With Huge Yields) Are Incredible Q3 Buys24/7 Wall Street • 06/23/22
Sanofi, GSK Covid Booster Triggers ‘Strong Immune Response' Against Multiple Variants Including OmicronForbes • 06/13/22
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including OmicronGlobeNewsWire • 06/13/22
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growthGlobeNewsWire • 06/08/22
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitisGlobeNewsWire • 06/07/22